Novavax, Inc. (NasdaqGS: NVAX)
Health Care · Biotechnology · US
$9.41
-0.32% today · +25.5% 1Y
Novavax, Inc. (NasdaqGS: NVAX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.56B and employs 749 people.
Over the last twelve months the share price has gained 25.5%, trading between 6.20 and 11.97.
Tweenvest scores Novavax, Inc. across four factors: quality 42/100, value 44/100, growth 100/100. Its strongest factor is growth.
NVAX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.56B
- Revenue (TTM)
- $413.80M
- P/E
- —
- EPS
- -1.52
- Dividend yield
- —
- Beta (5Y)
- 2.42
- 52-week high
- $11.97
- 52-week low
- $6.20
- Avg volume (3M)
- —
- Shares outstanding
- 164.95M
- Employees
- 749
- Next earnings
- —
About Novavax, Inc.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
- ISIN
- US6700024010
- Founded
- 1987
- Listed since
- Dec 5, 1995
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $156.05 | -1.75% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.